{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-23-002543","form_type":"8-K","ticker":"CATX","cik":"0000728387","company_name":"Perspective Therapeutics, Inc.","filed_at":"2023-02-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:47.911663+00:00","generated_at":"2026-06-20T00:37:07.720071+00:00","sec_items":["1.01","1.02","5.02","2.01","3.02","5.03","7.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Isoray closes all-stock merger with Viewpoint; Spoor named CEO, Woods Chair","bullets":["Completed all-stock merger with Viewpoint; issued 136.5M shares (49% of pro forma) at 3.1642 exchange ratio.","New CEO Thijs Spoor (ex-Viewpoint CEO) appointed; Lori Woods becomes Chairperson of the Board.","Woods receives $504K severance, accelerated vesting of 1,007,498 stock options under separation agreement.","Board expanded to five: Woods (Chair), Spoor, Morich, Williamson, and McCormick.","Fiscal year changed from June 30 to December 31; transition Form 10-KT to be filed."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-23-002543","json":"https://secwatch.observer/filing/0001437749-23-002543.json","markdown":"https://secwatch.observer/filing/0001437749-23-002543.md","text":"https://secwatch.observer/filing/0001437749-23-002543.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/728387/000143774923002543/0001437749-23-002543-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/728387/000143774923002543/isr20230204_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T00:37:07.720071+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4940eb98dc","claim":"Frank Morich was appointed as Director at Perspective Therapeutics, Inc..","evidence_excerpt":"(iv) Dr. Frank Morich as a director of the Company","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/728387/000143774923002543/0001437749-23-002543-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"6db4e5eb8e","claim":"Alan Hoffmann resigned as Director at Perspective Therapeutics, Inc..","evidence_excerpt":"Alan Hoffmann and Dr. Philip Vitale each gave notice of their resignation from the Board of Directors of the Company (the “ Board ”), effective upon the Closing.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/728387/000143774923002543/0001437749-23-002543-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"8b428138d6","claim":"Lori A. Woods resigned as Chief Executive Officer at Perspective Therapeutics, Inc..","evidence_excerpt":"On February 1, 2023, and effective upon the Closing, Lori A. Woods gave notice of her resignation as the Chief Executive Officer of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/728387/000143774923002543/0001437749-23-002543-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"8edaf42c44","claim":"Philip Vitale resigned as Director at Perspective Therapeutics, Inc..","evidence_excerpt":"Alan Hoffmann and Dr. Philip Vitale each gave notice of their resignation from the Board of Directors of the Company (the “ Board ”), effective upon the Closing.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/728387/000143774923002543/0001437749-23-002543-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"aa3716c70a","claim":"Johan (Thijs) Spoor was appointed as Chief Executive Officer at Perspective Therapeutics, Inc..","evidence_excerpt":"the Board appointed: (i) Johan (Thijs) Spoor as Chief Executive Officer and a director of the Company","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/728387/000143774923002543/0001437749-23-002543-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"c5eac8871a","claim":"Robert Froman Williamson, III was appointed as Director at Perspective Therapeutics, Inc..","evidence_excerpt":"(iii) Robert Froman Williamson, III as a director of the Company","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/728387/000143774923002543/0001437749-23-002543-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"f144a50ac9","claim":"Lori A. Woods was appointed as Chairperson of the Board at Perspective Therapeutics, Inc..","evidence_excerpt":"(ii) Lori A. Woods as Chairperson of the Board","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/728387/000143774923002543/0001437749-23-002543-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chairperson of the Board"}],"fact_type":"executive_change"},{"claim_id":"c635e4cb34831209e96973e720fa50064fa34044","claim":"Perspective Therapeutics, Inc.: The Board approved a change in the Company's fiscal year end from June 30 to December 31, effective immediately (effective 2023-01-31).","evidence_excerpt":"On January 31, 2023, the Board approved a change in the fiscal year end of the Company from June 30 to December 31.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/728387/000143774923002543/0001437749-23-002543-index.htm","confidence":0.99,"family_label":"Governance Changes","details":[{"label":"Change","value":"fiscal year change"},{"label":"Effective","value":"2023-01-31"}],"fact_type":"governance_change"},{"claim_id":"264270c144d3b5a35e2b33357c804108e936ed17","claim":"Perspective Therapeutics, Inc. completed an acquisition involving Viewpoint Molecular Targeting, Inc. (closed 2023-02-03).","evidence_excerpt":"On February 3, 2023 (the \" Closing Date \"), the Company completed the merger (the \" Closing \") of Isoray Acquisition Corp., a Delaware corporation and wholly-owned subsidiary of the Company (\" Merger Sub \"), with Viewpoint Molecular Targeting, Inc. (\" Viewpoint \") (such transaction being the \" Merger \").","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/728387/000143774923002543/0001437749-23-002543-index.htm","confidence":0.9,"family_label":"M&A Transactions","details":[{"label":"Action","value":"acquisition"},{"label":"Counterparty","value":"Viewpoint Molecular Targeting, Inc."},{"label":"Closing","value":"2023-02-03"}],"fact_type":"ma_transaction"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}